Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 23;18(1):163.
doi: 10.1186/s13023-023-02790-7.

A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act

Lewis J Fermaglich  1 , Kathleen L Miller  2
Affiliations

A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act

Lewis J Fermaglich et al. Orphanet J Rare Dis. .

Abstract

Background: Rare diseases affect more than 30 million Americans. The passage of the Orphan Drug Act (ODA) in the United States in 1983 represented a launching point for a rare disease drug development revolution for these patients. Financial incentives provided by the ODA through its Orphan Drug Designation Program, in addition to remarkable scientific advances over the past 40 years, have led to hundreds of drug approvals for rare diseases. Our research examines the rare diseases that have been targeted by orphan drug designations and subsequent approvals since the law was enacted.

Methods: Using an internal FDA database, we classified and analyzed all orphan drug designations and approvals from 1983 to 2022 by disease and therapeutic area.

Results: Over the 40 years of the ODA, 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases. Additionally, 882 of those designations resulted in at least one FDA approval for use in 392 rare diseases. Much of this development has been concentrated in oncology as seven of the top ten most designated and approved diseases were rare cancers.

Conclusions: Researchers have estimated that there may be 7000-10,000 rare diseases that have been identified and described. Based on our study, we can conclude that around 5% of rare diseases have an FDA-approved drug and up to 15% of rare diseases have at least one drug that has been developed and shown promise in their treatment, diagnosis or prevention. Funding of basic and translational science for rare disease drug development should continue in order to bring therapies to the millions of affected patients who remain without treatment options.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Total orphan drug designations (n = 6340) and initial orphan drug approvals (n = 882) by decade, 1983–2022
Fig. 2
Fig. 2
Few rare diseases account for a large percentage of orphan drug designations and initial orphan drug approvals, 1983–2022
See this image and copyright information in PMC

References

    1. Orphan Drug Act. P.L. 97–414 (Jan 4, 1983).
    1. Asbury CH. The Orphan Drug Act: the first 7 years. JAMA. 1991;265(7):893–897. doi: 10.1001/jama.1991.03460070075046. - DOI - PubMed
    1. Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–78. doi: 10.1038/d41573-019-00180-y. - DOI - PMC - PubMed
    1. Patel S, Miller Needleman KI. FDA's Office of Orphan Products Development: providing incentives to promote the development of products for rare diseases. J Pharmacokinet Pharmacodyn. 2019;46(5):387–393. doi: 10.1007/s10928-019-09645-4. - DOI - PubMed
    1. Orphan Drug Act. 21 USC § 360aa. 1983.